Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on GEHC stock, giving a Buy rating yesterday.
Anthony Petrone’s rating is based on a combination of factors that highlight GE Healthcare Technologies Inc’s (GEHC) strong position in the market. The company has effectively hedged potential risks from China with a robust performance in the US, particularly in radiology, which is expected to drive growth. The introduction of FLYRCADO, a new product, has been well-received, with projections indicating significant revenue contributions in the coming years.
Additionally, GEHC’s ability to navigate potential shifts in US healthcare policy without immediate negative impacts, along with securing large enterprise deals like the $1 billion Summit Health agreement, provides a solid foundation for future growth. The company’s shares are trading at a discount compared to peers, despite promising top-line growth and earnings projections, making it an attractive investment opportunity. These elements, combined with the potential for product launches and favorable coding for FLYRCADO, reinforce GEHC as a compelling choice for investors.
In another report released yesterday, Goldman Sachs also upgraded the stock to a Buy with a $100.00 price target.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GEHC in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com